Nanocellulose-based Smart Delivery Systems for Personalized Medicine

A next-generation nanocellulose-derived hydrogel drug delivery system that integrates machine learning, 3D printing, and wearable sensors to provide adaptive, personalized, and real-time controlled release of therapeutic agents.

The original patent's limitations in terms of fixed release kinetics, lack of real-time monitoring, and limited adaptability to patient needs are addressed by the new inventive concept, which envisions a paradigm shift towards smart, adaptive, and personalized drug delivery systems.

The new inventive concept comprises a range of nanocellulose-based implantable devices, hydrogels, and biohybrid materials that leverage machine learning algorithms, 3D printing, and wearable sensors to create personalized, adaptive, and real-time controlled release of therapeutic agents. The devices and materials are designed for minimally invasive implantation, remote triggering, and on-demand release, ensuring enhanced bioavailability, reduced immune response, and improved treatment outcomes.

The new claims introduce a novel combination of machine learning, 3D printing, and wearable sensors to create adaptive, personalized, and real-time controlled release of therapeutic agents, which is not obvious from the original patent and represents a significant inventive step.

Alternative embodiments of the inventive concept could include the use of different nanocellulose sources, variations in 3D printing techniques, and integration with other wearable devices or sensors to expand the scope of applications and improve treatment outcomes.

The inventive concept has significant commercial potential in the personalized medicine market, with applications in chronic disease management, cancer treatment, and gene therapy, among others. The target industries include pharmaceuticals, biotechnology, and medical devices.